High-dose Cephalexin for Cellulitis (HI-DOCC) | MicrobiomeTrials← Back to trialsNCT05852262
High-dose Cephalexin for Cellulitis (HI-DOCC)
CompletedPHASE4INTERVENTIONAL
Trial Details
Start: 2023-08-30Est. Completion: 2026-04-05
Enrollment target: 454 participants Locations- South Health Campus, Calgary, Alberta, Canada
- Queen Elisabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada
- Health Sciences North, Greater Sudbury, Ontario, Canada
- Kingston Health Sciences Centre, Kingston, Ontario, Canada
- London Health Sciences Centre, London, Ontario, Canada
- The Ottawa Hospital, Ottawa, Ontario, Canada
- Thunder Bay Health Sciences Centre, Thunder Bay, Ontario, Canada
- Sinai Health System, Toronto, Ontario, Canada
- Hôpital du Sacré-Cœur de Montréal, Montreal, Quebec, Canada
- Enfant-Jésus Hospital, Québec, Quebec, Canada
Other microbiome trials you might be interested in
ScabiesAtopic DermatitisSecondary Bacterial Skin Infection
This prospective observational study will evaluate the microbiological profile of secondary bacterial infection and nasa…
Istanbul, Turkey (Türkiye)Est. completion Mar 2027
Odontogenic InfectionMaxillofacial InfectionCellulitisCellulitis of FaceAbscess
We are conducting a trial to compare moxifloxacin against clindamycin for dental infections that spread to the face and …
Multan, PakistanEst. completion Jan 30, 2027
Peritonsillar AbscessPeritonsillar CellulitisTonsillitis
Peritonsillar abscess (PTA) is a collection of pus between the palatine tonsil and the constrictor muscle. PTA is detect…
Copenhagen, DenmarkEst. completion Jul 15, 2026